Tag Archives: NYSE MKT:TXMD

Oppenheimer Sticks to Their Buy Rating for TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report) today and set a price target of $14. The company’s shares closed yesterday at $5.09. Olson noted: “TXMD reported 4Q results and launch progress for 2019

Oppenheimer Reaffirms Their Buy Rating on TherapeuticsMD (TXMD)

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed on Friday at $5.23. Olson observed: “TXMD provided an update on the Imvexxy launch

TherapeuticsMD (TXMD) Gets a Buy Rating from Oppenheimer

Oppenheimer analyst Jay Olson maintained a Buy rating on TherapeuticsMD (TXMD – Research Report) yesterday and set a price target of $14. The company’s shares closed yesterday at $5.10. Olson said: “We met management for an update on Imvexxy launch

Cantor Fitzgerald Reiterates a Buy Rating on TherapeuticsMD (TXMD)

Cantor Fitzgerald analyst Louise Chen reiterated a Buy rating on TherapeuticsMD (TXMD – Research Report) today and set a price target of $27. The company’s shares closed on Friday at $5.11. Chen observed: “We reiterate our OW rating. The execution

Analysts’ Top Healthcare Picks: TherapeuticsMD (TXMD), Heron Therapeutics (HRTX)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on TherapeuticsMD (TXMD – Research Report), Heron Therapeutics (HRTX – Research Report) and Immunomedics (IMMU – Research Report) with bullish sentiments. TherapeuticsMD (TXMD)

Oppenheimer Thinks TherapeuticsMD’s Stock is Going to Recover

In a report released today, Jay Olson from Oppenheimer maintained a Buy rating on TherapeuticsMD (NYSE MKT: TXMD), with a price target of $14. The company’s shares opened today at $4.76, close to its 52-week low of $4.34. Olson noted: